Palisade Bio Stock Shares Outstanding
PALI Stock | USD 2.44 0.01 0.41% |
Palisade Bio fundamentals help investors to digest information that contributes to Palisade Bio's financial success or failures. It also enables traders to predict the movement of Palisade Stock. The fundamental analysis module provides a way to measure Palisade Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Palisade Bio stock.
The Palisade Bio's current Common Stock Shares Outstanding is estimated to increase to about 478.8 K. Palisade | Shares Outstanding |
Palisade Bio Company Shares Outstanding Analysis
Palisade Bio's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Palisade Bio Shares Outstanding | 1.33 M |
Most of Palisade Bio's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Palisade Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Palisade Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Palisade Bio is extremely important. It helps to project a fair market value of Palisade Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Palisade Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Palisade Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Palisade Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Palisade Shares Outstanding Historical Pattern
Today, most investors in Palisade Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Palisade Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Palisade Bio shares outstanding as a starting point in their analysis.
Palisade Bio Shares Outstanding |
Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Palisade Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Palisade Bio has 1.33 M of shares currently outstending. This is 99.26% lower than that of the Biotechnology sector and 98.76% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 99.77% higher than that of the company.
Palisade Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Palisade Bio's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Palisade Bio could also be used in its relative valuation, which is a method of valuing Palisade Bio by comparing valuation metrics of similar companies.Palisade Bio is currently under evaluation in shares outstanding category among its peers.
Palisade Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Palisade Bio from analyzing Palisade Bio's financial statements. These drivers represent accounts that assess Palisade Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Palisade Bio's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 513.3M | 167.9M | 219.7M | 4.0M | 4.6M | 4.4M | |
Enterprise Value | 512.5M | 162.9M | 220.4M | (8.0M) | (9.2M) | (8.8M) |
Palisade Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Palisade Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Palisade Bio's managers, analysts, and investors.Environmental | Governance | Social |
Palisade Fundamentals
Return On Equity | -1.1 | ||||
Return On Asset | -0.59 | ||||
Current Valuation | (3.95 M) | ||||
Shares Outstanding | 1.33 M | ||||
Shares Owned By Insiders | 1.88 % | ||||
Shares Owned By Institutions | 3.57 % | ||||
Number Of Shares Shorted | 43.11 K | ||||
Price To Earning | 0.16 X | ||||
Price To Book | 0.56 X | ||||
Price To Sales | 14.03 X | ||||
Revenue | 250 K | ||||
EBITDA | (12.28 M) | ||||
Net Income | (12.3 M) | ||||
Cash And Equivalents | 5 M | ||||
Cash Per Share | 0.23 X | ||||
Total Debt | 369 K | ||||
Debt To Equity | 0.23 % | ||||
Current Ratio | 2.59 X | ||||
Book Value Per Share | 18.30 X | ||||
Cash Flow From Operations | (11.13 M) | ||||
Short Ratio | 0.29 X | ||||
Earnings Per Share | (13.26) X | ||||
Target Price | 30.33 | ||||
Beta | 1.33 | ||||
Market Capitalization | 3.73 M | ||||
Total Asset | 14.05 M | ||||
Retained Earnings | (121.51 M) | ||||
Working Capital | 10.74 M | ||||
Net Asset | 14.05 M |
About Palisade Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Palisade Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Palisade Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Palisade Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:Check out Palisade Bio Piotroski F Score and Palisade Bio Altman Z Score analysis. For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.26) | Return On Assets (0.59) | Return On Equity (1.10) |
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.